menu
    • menu
    [{"orgOrder":0,"company":"Venture Life","sponsor":"Jaguar Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Venture Life","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Venture Life \/ Jaguar Health","highestDevelopmentStatusID":"15","companyTruncated":"Venture Life \/ Jaguar Health"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"ADM\/Matsutani LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ ADM\/Matsutani LLC","highestDevelopmentStatusID":"1","companyTruncated":"University of Florida \/ ADM\/Matsutani LLC"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Roquette Freres","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Roquette Freres","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roquette Freres \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Roquette Freres \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Roquette Freres","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Roquette Freres","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roquette Freres \/ BioFortis","highestDevelopmentStatusID":"1","companyTruncated":"Roquette Freres \/ BioFortis"}]

    Find Clinical Drug Pipeline Developments & Deals for Maltodextrin

    Menu

    Maltodextrin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jaguar Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jaguar Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jaguar Health Launches Oral Mucositis Product Gelclair in U.S.

                            Details : Gelclair (maltodextrin) is indicated to alleviate pain by adhering to the mucosal surface of the mouth and treating oral lesions, including oral mucositis/stomatitis.

                            Product Name : Gelclair

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 16, 2024

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Venture Life

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Venture Life

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Jaguar Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jaguar Licenses Oral Mucositis Product for U.S. Market in Cancer Care

                            Details : Gelclair will be commercialized by Jaguar Health in the U.S. to alleviate pain from oral lesions, including mucositis and stomatitis.

                            Product Name : Gelclair

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Jaguar Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Roquette Freres

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Roquette Freres

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : BioFortis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of Daily Supplementation of Nutriose® on the Fecal Microbiota in Volunteers.

                            Details : Nutriose is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 03, 2021

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : BioFortis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Probiotic BL NCC 2705 and Gluten Sensitivity

                            Details : Maltodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Celiac Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 14, 2018

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of Florida

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Florida

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : ADM/Matsutani LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Resistant Maltodextrin Supplementation: Gastrointestinal Health

                            Details : Maltodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2016

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : ADM/Matsutani LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fiber Tolerability in Children

                            Details : Maltodextrin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Signs and Symptoms, Digestive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 10, 2015

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Roquette Freres

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Roquette Freres

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Sprim Advanced Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of NUTRIOSE®FB Dietary Fiber Supplementation on Satiety, Body Fat, and Metabolic Syndrome in Overwe...

                            Details : Nutriose is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            January 08, 2010

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Sprim Advanced Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth